Fosun Pharma: Controlling subsidiary's drug approved for clinical trials

Fosun Pharma announced that its controlling subsidiary, Shanghai Fuhong Hanlin Biotech Co., Ltd., and its subsidiaries have received approval from the National Medical Products Administration to conduct Phase I clinical trials of HLX316 injection for the treatment of advanced/metastatic solid tumors.

View Original
This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin